- Polpharma Biologics’ Ranivisio® PFS, a ranibizumab biosimilar pre-filled syringe, is now commercially available in France.
- The drug substance is manufactured by Polpharma Biologics’ CDMO, Rezon Bio, under the Bioeq joint venture, with Teva holding exclusive commercialisation rights in France.
Polpharma Biologics has announced that Ranivisio® PFS, a ranibizumab biosimilar pre-filled syringe, is now commercially available in France. The launch marks the first Lucentis® biosimilar offered in a pre-filled syringe format in Europe.
Ranivisio® PFS is intended for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). The pre-filled syringe format aims to provide precise dosing and ease of use, supporting efficient administration in clinical settings.
The biosimilar was developed and licensed by Bioeq AG, a joint venture between Polpharma Biologics Group BV and Formycon AG. Commercialisation in France is managed by Teva under an exclusive licensing agreement with Bioeq.
The drug substance for Ranivisio® PFS is produced by Polpharma Biologics S.A., a CDMO operating under the Rezon Bio brand, at its facilities in Poland. Rezon Bio is responsible for the commercial supply, ensuring consistent quality and reliability for the European market.
“The launch of Ranivisio® PFS in France is another important step in our mission to broaden access to biologic medicines. With the first Lucentis® biosimilar available in a pre-filled syringe in Europe, we are setting a new standard for ophthalmic treatment.”
Anjan Selz, CEO of Polpharma Biologics
